← Leaderboards
Barry P Hart
Innovation Pathways, Llc
$600,000
Attributed
$600,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2018–19$500K$375K$250K$125K$0
'18
'19
Funding mix
By agency
NIH$600,000 · 1
By mechanism
R43$600,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Advanced Development”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Joel A Lipkin · Four Points Technology, Llc$181,896,915
- Kimberly Smith · Ppd Development Lp$115,671,664
Research focus
Advanced DevelopmentAnimal ModelAnimalsBioavailableBody SystemBreathingC57bl/6 MouseCardiopulmonaryCessation Of LifeChestCitrullineClinical TrialsCollagenConnective Tissue Growth FactorControl AnimalCsf3 GeneDisabilityDoseDose-RateDrug KineticsEffective TherapyEvaluationEventAcute
Grant awards (2)
Evaluation of IPW-5371, a TGFbRI kinase inhibitor, dosed as a single agent or in combination with G-CSF, as a medical countermeasure against the delayed effects of total body irradiation in mice$300,000
R43 · FY2019 · AI · contact PI
Evaluation of IPW-5371, a TGFbRI kinase inhibitor, dosed as a single agent or in combination with G-CSF, as a medical countermeasure against the delayed effects of total body irradiation in mice$300,000
R43 · FY2018 · AI · contact PI